| Name | Title | Contact Details |
|---|---|---|
Jacques Essinger |
Chairman and Chief Executive Officer | Profile |
Classical Homeopathy is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
option one is a Corona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In 1993, a novel technology was invented by a team that included Jon Faiz Kayyem, PhD at The California Institute of Technology (CalTech). This invention combined nucleic acids and microelectronics to produce an electronic sensor for DNA detection. His invention was based on electrical detection of nucleic acids on a cassette based detection platform. Dr. Kayyem went on to found Clinical Micro Sensors, with the goal of translating this “eSensor” technology to disposable chips. Following several acquisitions of the technology, Dr. Kayyem became actively involved again in 2009, returning as an investor and then as CEO and Chairman of the Board. In 2009, a collaboration between Dr. Kayyem and Christopher Gleeson began. The two redefined the company strategy, and brought in a new board of directors, executive leadership team, and commercial management. In 2010, the company known at that time as Osmetech, was named GenMark Diagnostics and listed on NASDAQ. Mr. Gleeson remained an integral part of GenMark`s growth in the years that followed, serving as Chairman of the Board until his retirement in 2014. Dr. Kayyem currently serves as SVP, Research and Development.
Elixir Medical Corporation, a privately-funded company based in Milpitas, California, develops next-generation platforms to treat coronary and peripheral artery disease that are designed to restore the adaptive remodeling and pulsatile motion capabilities of the blood vessel. The company`s mission is to transform the care of patients with heart and vascular disease through innovation.
Vermillion`s vision is to become a recognized leader in the advancement of women`s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases. We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.